Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2006-10-03
2006-10-03
Spivack, Phyllis G. (Department: 1614)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C514S459000, C514S336000, C514S365000, C514S452000, C514S364000, C514S378000, C514S405000, C514S326000, C514S231500, C514S422000, C514S259310, C514S384000, C514S397000, C514S262100, C514S456000, C514S258100, C514S382000, C514S255050, C514S369000, C514S274000, C514S340000, C514S363000, C514S375000, C514S254100
Reexamination Certificate
active
07115658
ABSTRACT:
Compounds of formula I are hepatitis C virus (HCV) RNA-dependent RNA polymerase (RdRp) inhibitors, and are useful in therapeutic and prophylactic treatment of persons infected with hepatitis C virus
REFERENCES:
patent: 3786063 (1974-01-01), Arnold
patent: 4326058 (1982-04-01), Okabe et al.
patent: 4489077 (1984-12-01), Sircar et al.
patent: 4591583 (1986-05-01), Helgstrand et al.
patent: 5504104 (1996-04-01), Ellsworth et al.
patent: 5789440 (1998-08-01), Ellsworth et al.
patent: 5808062 (1998-09-01), Domagala et al.
patent: 5834506 (1998-11-01), Boyer, Jr. et al.
patent: 5840751 (1998-11-01), Ellsworth et al.
patent: 5846964 (1998-12-01), Ozeki
patent: 5936128 (1999-08-01), Ellsworth et al.
patent: 6046355 (2000-04-01), Boyer, Jr. et al.
patent: 6174868 (2001-01-01), Anderson et al.
patent: 6512006 (2003-01-01), Boyer, Jr. et al.
patent: 6528510 (2003-03-01), Boyer, Jr. et al.
patent: 2003/0171425 (2003-09-01), Boyer, Jr., et al.
patent: 2003/0195239 (2003-10-01), Borchardt et al.
patent: 1 256 628 (2002-11-01), None
patent: WO 94 11361 (1994-05-01), None
patent: WO 95 14011 (1995-05-01), None
patent: WO 95 14012 (1995-05-01), None
patent: WO 98 19997 (1998-05-01), None
patent: WO 00 15634 (2000-03-01), None
patent: WO 0015634 (2000-03-01), None
patent: WO 00 40237 (2000-07-01), None
Allen, C.F., et al. “The Structure of Certain Polyazaindenes. III. 1,2,3a,7-and 1,3,3a,7-Tetrazaindenes,”J. Org. Chem,1959, pp. 793-796, vol. 24.
Bergman, J., et al., “Synthesis of Chrysogine, a Metabolite of Penicillium Chrysogenum and Some Related 2-substituted 4-(3H)-Quinazolinones,”Tetrahedron, 1990, pp. 1295-1310, vol. 46.
Burke, T.R., et al., “Conformationallly Constrained Phosphotyrosyl Mimetics Designed As Monomeric Src Homology 2 Domain Inhibitors,”J. Med. Chem.1995, pp. 1386-1396, vol. 38.
Carvalho, C.F., et al., “Naturally Occurring Dibenzofurans. Part 6. Synthesis Of Didymic Acid,”J. Chem Soc. Perkin Trans 1, 1984, pp. 1621-1626.
Chavignon, O., et al., “Pyrrolization Processes Of Vinyl Substituted Imidazol[1,2-α]pyridine, Pyrimidine And 1,8-Naphthyridine,”J. Heterocyclic Chem., 1992, pp. 691-697, vol. 29.
Doria, G., et al, “7-Z-Trans-(2-Pyridylethenyl)-5H-Thiazolo[3,2-a] Pyrimidine-5-Ones: Synthesis and Pharmacological Activity,”Farmaco Ed. Sci.,1985, pp. 885-895.
Ellsworth, E.L., et al., “4 Hydroxy -5,6-Dihydro-2H-Pyran-2-ones. 3.Bicyclic and Hetero-Aromatic Ring Systems as 3-Position Scaffolds to Bind to S1' and S2' of the HIV-1 Protease Enzyme,”Biporg. Med. Chem. Lett.,1999, pp. 2019-2024, vol. 9, issue 14.
Halimorad et al., “Some observations on the Binding Properties of Alfalfa Mosaic Virus to Polystyrene and its Significance to Indirect ELISA,”Arch. Virol.,1991, pp. 219-235, vol. 2.
Gerecke, M., et al, “New Tetracyclic Derivatives of Imidazo-[1,5-a][1,4]Benzodiazepines and of Imidazo [1,5-a]Thieno[3,2-f][1,4]Diazepines,”Heterocycles, 1994, pp. 693-721, vol. 39, No. 2.
Hagen, S., et al., “Synthesis of 5,6-Dihydro-4-hydroxy-2-pyrones as HIV-1 Protease Inhibitors: The Profound Effect of Polarity on Antiviral Activity,”J. Med Chem.,1997, pp. 3707-3711, vol. 40, issue 23.
Hénichart, J., et al., “A Convenient Method For The Preparation of ω-Di-Alkylaminoalkyl Isothiocyanates,”Synthesis, 1980, pp. 311-312.
Ishizumi, K. et al., “Synthesis and Anxiolytic Activity ofN-Substituted Cyclic Imides 91R*, 2S*,3R*, 4S*)-N-[4[4-(2-Pyrimidinyl)-1-Piperazinyl]butyl]-2,3-Bicyclo[2.2.1]Heptanedicarboximide (Tandospirone) And Related Compounds,”Chem. Pharm Bull.,1991, pp. 2288-2300, vol. 39, No. 9.
Kuchar, M., et al., “The Synthesis of Arylpropionic Acids and The Quantitative Relationship Between the Structure and the Activation of Fibrinolysis,”Collect. Czech. Chem. Commun, 1981, pp. 1173-1187, vol. 46.
Lee, Y.R., et al., “A New Route For The Synthesis of Furanoflavone and Furanochalcone Natural Products,”Tetrahedron, 1995, pp. 4909-4922, vol. 51.
Moloney, G.P, et al., “Synthesis and Serotonergic Activity of 2-oxadiazolyl-5-substituted-N,N-dimethyltryptamines: Novel Antagonists for the Vascular 5-HT1b-like Receptor”J. Chem. Soc Perkin, 1999, pp. 2725-2733, vol. 19.
Mylari, B.L., et al., “Potent, Orally Active Aldose Reductase Inhibitors Related to Zopolrestat: Surrogates For Benzothiazole Side Chain,”J. Med. Chem., 1992, pp. 457-465, vol. 35, issue 3.
Palazzo, G, et al., “1,2,4-Oxadiazoles—IV. Synthesis and Pharmacological Properties of a Series of Substituted Aminoalkyl-1,2,4-oxadiazoles,”J. Med. Pharm. Chem.,1961, pp. 351-367, vol. 4, issue 2.
Powell, M.T., et al, “Optically activeC3-Symmetric Triarylphosphines in Asymmetric Allylations,”Tetrahedron, 2001, pp. 5027-5038, vol. 57.
Ren, R., et al., “Total Synthesis Of The Ocular Age Pigment A2-E: A Convergent Pathway,”J. Am. Chem. Soc., 1997, pp. 3619-3620, vol. 119.
Selassie, C., et al., “QSAR For The Cytotoxicity of 2-Alkyl or 2,6-Dialkyl, 4-X-Phenols: The Nature of the Radical Reaction,”J. Chem. Soc. Perkin Trans 2, 2002, pp. 1112-1117.
Shishoo, C. J., et al., “Reaction of Nitriles Under Acidic Conditions. Part III. A Facile Synthesis of Thienopyrimidin-4(3H)-ones,”J. Heterocyclic Chem.,1984, pp. 375-380, vol. 21.
Szmuszkovicz, J., et al., “A Study Of The Inhibitory Effect Of Various Hydrazides On Monoamine Oxidasein vitroAndin vivo,” Journal Of Medicinal And Pharmaceutical Chemistry,1961, pp. 259-296, vol. 4, No. 2.
Vara Prasad, J.V.N., et al., “Nonpeptidic HIV Protease Inhibitors: 6-Alkyl-5,6-Dihydropyran-2-Ones Possessing Achiral 3-(4-Amino/Carboxamide-2-t-Butyl, 5-Methylphenyl Thio) Moiety: Antiviral Activities and Pharmacokinetic Properties,”Bioorg. Med. Chem. Lett., (Jul. 6, 1999), pp. 1481-1486, vol. 9, issue 11.
Vara Prasad, et al., “Nonpeptidic HIV Protease Inhibitors Processing Excellent Antiviral Activities and Therapeutic Indices. PD 178390: A Lead HIV Protease Inhibitor”,Bioorganic Medicinal Chemistry Letters, 1999, pp. 2775-2800.
Baginski S., et al., “Mechanism of Action Of A Pestivirus Antiviral Compound”Proc. Natl. Acad. Sci. USA(2000) pp. 7981-7986, vol. 97.
Bagshawe, “Antibody-Directed Enzyme Prodrug Therapy: A Review”,Drug Dev. Res., 1995, pp. 220-230, vol. 34.
Bartenschlager, et al., “Molecular Targets In Inhibition Of Hepatitis C Virus Replication”Antiviral Chemistry&Chemotherapy1997, pp. 281-301, vol. 8, No. 4.
Bartenschlager, et al., “Nonstructural Protein 3 Of The Hepatitis C Virus Encodes A Serine-Type Proteinase Required For Cleavage At The NS3/4 And NS4/5 Junctions”Journal of Virology, Jul. 1993, pp. 3835-3844, vol. 67, No. 7.
Bertolini, et al., “A New Rational Hypothesis for the Pharmacophore of the Active Metabolite of Leflunomide, a Potent Immunosuppressive Drug”,J. Med. Chem., 1997, pp. 2011-2016, vol. 40.
Bodor, “Novel Approaches to the Design of Safer Drugs: Soft Drugs and Site-Specific Chemical Delivery Systems”,Advances in Drug Res.,1984, pp. 224-331, vol. 13.
Boyer, et al., 5,6-Dihydropyran-2-ones Possessing Various Sulfonyl Functionalities: Potent Nonpeptidic Inhibitors of HIV Protease,J. Med. Chem., 2000, pp. 843-858, vol. 43, No. 5.
Brown, et al., “Secondary Structure Of The 5′Nontranslated Regions of Hepatitis C Virus And Pestivirus Genomic RNAs”Nucleic Acids Research,1992, pp. 5041-5045, vol. 20, No. 19.
Bukh, et al., “Sequence Analysis Of The 5′ Noncoding Region Of Hepatitis C Virus”Proc. Natl. Acad. Sci. USA, Jun. 1992, pp. 4942-4946, vol. 89.
Bundgaard,Design of Prodrugs(Elsevier Press, 1985).
Choo, et al., “Isolation of a cDNA Clone Derived From A Blood-Borne Non-A, Non-B Viral Hepatitis Genome”Science, Apr. 21, 1989, pp. 359-362, vol. 244.
Cuthbert, J., “Hepatitis C: Progress and Problems”Cli
Abreo Melwyn A.
Borchardt Allen J.
Dragovich Peter Scott
Gonzalez Javier
Jewell Tanya Michelle
Agouron Pharmaceuticals , Inc.
Spivack Phyllis G.
Tidwell Jeffrey H.
Zielinski Bryan C.
LandOfFree
Inhibitors of hepatitis C virus RNA-dependent RNA polymerase does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Inhibitors of hepatitis C virus RNA-dependent RNA polymerase, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Inhibitors of hepatitis C virus RNA-dependent RNA polymerase will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3679799